Denali Therapeutics (DNLI)
(Real Time Quote from BATS)
$23.73 USD
+0.20 (0.85%)
Updated Jul 23, 2024 10:48 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
DNLI 23.73 +0.20(0.85%)
Will DNLI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DNLI
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
Denali (DNLI) Outperforms Industry in 3 Months: Here's Why
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
Other News for DNLI
Denali Therapeutics management to meet with Oppenheimer
Denali Therapeutics management to meet with Oppenheimer
JPMorgan smid & large cap biotech analysts hold analyst/industry conference call
JPMorgan smid & large cap biotech analysts hold analyst/industry conference call
ALS therapy market seen increasing to nearly $1.3B by 2029